Thromboses and Hemorrhages are Common in MPN Patients with High JAK2V617F Allele Burden
The most common causes of morbidity and mortality in patients with myeloproliferative neoplasms (MPNs) are thrombotic and hemorrhagic complications. The JAK2V617F mutation, commonly found in MPNs, correlates with several clinical and laboratory characteristics even if the relevance of JAK2V617F allele burden in the natural history of these diseases is unclear. The researchers in this study suggest that patients with MPNs with JAK2V617F allele burden higher than 75% should be considered high-risk patients, being prone to develop thrombo-hemorrhagic complications during the course of the disease.
Ann Hematol
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology